Hua Xiong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hua Xiong has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
Xianglin Yuan
10 shared publicationsHong Zhang
8 shared publications- Yanmei Zou
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST)
8 shared publications Yanmei Zou
6 shared publications- Yihua Wang
University of Southampton
6 shared publications Chenlin Cao
5 shared publications
Latest Publications
- 20 May 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- p. 1-18
PARK7-induced delactylation of ATAD3A impairs mitochondrial fitness to promote exhaustion of tumor-infiltrating CD8+ T cells
Mitochondrial dysfunction is a critical factor driving the exhaustion of tumor-infiltrating CD8+ T cells and impeding the efficacy of tumor immunotherapy. However, the key regulatory proteins and molecular mechanisms governing mitochondrial function in CD8+ T cells remain enigmatic. Here, we report that PARK7 is significantly enriched in the mitochondria of tumor-infiltrating CD8+ T cells. T-cell-specific PARK7 deficiency enhanced mitochondrial function in CD8+ T cells, alleviated T-cell exhaustion, and suppressed tumor growth. Mechanistically, we found that PARK7 directly interacted with the mitochondrial membrane protein ATAD3A and downregulated its lactylation level, thereby suppressing the expression of mitochondrial-related genes and ultimately promoting CD8+ T-cell exhaustion. Overall, our study not only identifies the critical role of PARK7 in regulating mitochondrial function in CD8+ T cells but also elucidates the molecular mechanism through which the PARK7-ATAD3A axis modulates mitochondrial gene expression, providing a potential therapeutic strategy for targeting PARK7 in tumor immunotherapy.
- 20 May 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- p. 1-18
PARK7-induced delactylation of ATAD3A impairs mitochondrial fitness to promote exhaustion of tumor-infiltrating CD8+ T cells
Mitochondrial dysfunction is a critical factor driving the exhaustion of tumor-infiltrating CD8+ T cells and impeding the efficacy of tumor immunotherapy. However, the key regulatory proteins and molecular mechanisms governing mitochondrial function in CD8+ T cells remain enigmatic. Here, we report that PARK7 is significantly enriched in the mitochondria of tumor-infiltrating CD8+ T cells. T-cell-specific PARK7 deficiency enhanced mitochondrial function in CD8+ T cells, alleviated T-cell exhaustion, and suppressed tumor growth. Mechanistically, we found that PARK7 directly interacted with the mitochondrial membrane protein ATAD3A and downregulated its lactylation level, thereby suppressing the expression of mitochondrial-related genes and ultimately promoting CD8+ T-cell exhaustion. Overall, our study not only identifies the critical role of PARK7 in regulating mitochondrial function in CD8+ T cells but also elucidates the molecular mechanism through which the PARK7-ATAD3A axis modulates mitochondrial gene expression, providing a potential therapeutic strategy for targeting PARK7 in tumor immunotherapy.
- Open Access
- 23 April 2026
- Published by Wiley in Cell Proliferation
- Vol. 59 (10) , e70210
Human Pancreatic Cancer Organoids
This guideline establishes a comprehensive framework for the application of patient-derived pancreatic cancer organoids. It outlines the stringent technical requirements and testing methods necessary to ensure high fidelity to the original tumor tissue, including morphological assessment, pathological biomarker expression (e.g., CK19, CK7), and genetic concordance (e.g., NRG1, KRAS). By standardizing protocols for in vitro culture, microbiological safety, and STR authentication, this consensus aims to ensure the reproducibility, safety, and stability of organoid models, thereby accelerating their integration into basic research, drug discovery, and precision medicine.
- 23 April 2026
- Published by Wiley in Cell Proliferation
- Vol. 59 (10) , e70210
Open AccessHuman Pancreatic Cancer Organoids
This guideline establishes a comprehensive framework for the application of patient-derived pancreatic cancer organoids. It outlines the stringent technical requirements and testing methods necessary to ensure high fidelity to the original tumor tissue, including morphological assessment, pathological biomarker expression (e.g., CK19, CK7), and genetic concordance (e.g., NRG1, KRAS). By standardizing protocols for in vitro culture, microbiological safety, and STR authentication, this consensus aims to ensure the reproducibility, safety, and stability of organoid models, thereby accelerating their integration into basic research, drug discovery, and precision medicine.
- Open Access
- 14 April 2026
- Published by Springer Nature in Amino Acids
- Vol. 58 (1)
Reprogramming of nitrogen metabolism in tumors: mechanisms and therapeutic implications
Nitrogen metabolism plays a key role in maintaining normal physiological functions of the organism and cell proliferation and differentiation. Nitrogen metabolism in normal human body maintains a dynamic balance to meet the body's demand for synthesis of biological macromolecules such as proteins and nucleic acids. However, in the process of tumor development, the nitrogen metabolism of tumor cells is reprogrammed to meet the demand of rapid proliferation, showing significantly different metabolic characteristics from normal cells. Key enzymes in the tumor microenvironment affect nitrogen metabolism through multiple mechanisms, providing essential nitrogen sources and energy for tumor cells. In-depth exploration of the regulatory mechanisms of tumor nitrogen metabolism not only helps to reveal the molecular basis of tumor development, but also provides a theoretical basis for the development of new tumor therapeutic strategies. In this paper, the relationship between nitrogen metabolism and tumors is systematically elaborated from the characteristics of nitrogen metabolism in normal people, the reprogramming of nitrogen metabolism in tumor patients, the influence of key enzymes on nitrogen metabolism in the tumor microenvironment, as well as the mechanism of tumor nitrogen metabolism regulation, etc., so as to provide references for the related research.
- 14 April 2026
- Published by Springer Nature in Amino Acids
- Vol. 58 (1)
Open AccessReprogramming of nitrogen metabolism in tumors: mechanisms and therapeutic implications
Nitrogen metabolism plays a key role in maintaining normal physiological functions of the organism and cell proliferation and differentiation. Nitrogen metabolism in normal human body maintains a dynamic balance to meet the body's demand for synthesis of biological macromolecules such as proteins and nucleic acids. However, in the process of tumor development, the nitrogen metabolism of tumor cells is reprogrammed to meet the demand of rapid proliferation, showing significantly different metabolic characteristics from normal cells. Key enzymes in the tumor microenvironment affect nitrogen metabolism through multiple mechanisms, providing essential nitrogen sources and energy for tumor cells. In-depth exploration of the regulatory mechanisms of tumor nitrogen metabolism not only helps to reveal the molecular basis of tumor development, but also provides a theoretical basis for the development of new tumor therapeutic strategies. In this paper, the relationship between nitrogen metabolism and tumors is systematically elaborated from the characteristics of nitrogen metabolism in normal people, the reprogramming of nitrogen metabolism in tumor patients, the influence of key enzymes on nitrogen metabolism in the tumor microenvironment, as well as the mechanism of tumor nitrogen metabolism regulation, etc., so as to provide references for the related research.
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (4) , 98
Identification of prognostic biomarkers and immunotherapy response predictors in lung adenocarcinoma: integrative Mendelian randomization and machine learning analysis
Background: Lung adenocarcinoma (LUAD), the most prevalent and clinically heterogeneous form of lung cancer, lacks robust biomarkers for prognosis and immunotherapy response prediction. This study aimed to identify key prognostic genes and develop a predictive framework to guide personalized treatment strategies. Methods: We integrated summary data-based Mendelian randomization (SMR) with machine learning to identify LUAD-associated genes. RNA-sequencing and clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were analyzed. A prognostic model was constructed with 101 combinations of 10 machine learning algorithms and validated via receiver operating characteristic (ROC) curve and concordance index analyses. Single-cell RNA-sequencing and spatial transcriptomic data were further examined to clarify the therapeutic implications of the identified genes. Results: SMR identified 316 LUAD-associated genes, among which 33 were associated with prognosis according to univariate Cox regression. The optimal model combining random survival forest and ridge regression achieved superior predictive accuracy, with the area under the curves for 1-, 3-, and 5-year survival being 0.757, 0.707, and 0.686, respectively. High-risk patients exhibited distinct immune microenvironment suppression, reduced tumor mutation burden, and diminished immunotherapy responsiveness as compared to their low-risk counterparts. Single-cell and spatial transcriptomic analyses identified interactions between cancer cells and stromal cells as potential therapeutic targets. Conclusions: The integrative approach employed in this study identified prognostic biomarkers and immunotherapy response predictors for patients with LUAD, offering a machine learning-driven framework for risk stratification and precision oncology. The findings underscore the clinical utility of combining genetic epidemiology with advanced analytics to optimize therapeutic strategies.
- 1 April 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (4) , 98
Open AccessIdentification of prognostic biomarkers and immunotherapy response predictors in lung adenocarcinoma: integrative Mendelian randomization and machine learning analysis
Background: Lung adenocarcinoma (LUAD), the most prevalent and clinically heterogeneous form of lung cancer, lacks robust biomarkers for prognosis and immunotherapy response prediction. This study aimed to identify key prognostic genes and develop a predictive framework to guide personalized treatment strategies. Methods: We integrated summary data-based Mendelian randomization (SMR) with machine learning to identify LUAD-associated genes. RNA-sequencing and clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were analyzed. A prognostic model was constructed with 101 combinations of 10 machine learning algorithms and validated via receiver operating characteristic (ROC) curve and concordance index analyses. Single-cell RNA-sequencing and spatial transcriptomic data were further examined to clarify the therapeutic implications of the identified genes. Results: SMR identified 316 LUAD-associated genes, among which 33 were associated with prognosis according to univariate Cox regression. The optimal model combining random survival forest and ridge regression achieved superior predictive accuracy, with the area under the curves for 1-, 3-, and 5-year survival being 0.757, 0.707, and 0.686, respectively. High-risk patients exhibited distinct immune microenvironment suppression, reduced tumor mutation burden, and diminished immunotherapy responsiveness as compared to their low-risk counterparts. Single-cell and spatial transcriptomic analyses identified interactions between cancer cells and stromal cells as potential therapeutic targets. Conclusions: The integrative approach employed in this study identified prognostic biomarkers and immunotherapy response predictors for patients with LUAD, offering a machine learning-driven framework for risk stratification and precision oncology. The findings underscore the clinical utility of combining genetic epidemiology with advanced analytics to optimize therapeutic strategies.
- Open Access
- 3 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (5) , 11365-11375
Causal associations of sarcopenia-related traits with selected site-specific cancers and the mediating role of gastroesophageal reflux disease
Background: Both sarcopenia and cancers are common geriatric diseases leading to huge socioeconomic burdens. The causal impact of sarcopenia on selected site-specific cancers and the potential mediator was not clarified. Methods: Two-step, two-sample Mendelian randomization was performed to explore the causal impacts of sarcopenia on selected site-specific cancers with or without adjustment for body fat percentage (BF%), physical activity and smoking, and to evaluate proportions of the causal effects mediated by gastroesophageal reflux disease (GERD). Genetic instruments of sarcopenia-related traits, GERD, and selected site-specific cancers based on genome-wide association study were obtained from the UK Biobank, TRICL, and Japan Biobank. By searching relevant studies in PubMed, EMBASE, Cochrane Library, and Web of Science, we collected the data on the prognostic effects of sarcopenia on non-small cell lung cancer (NSCLC) for meta-analysis. Results: Lower appendicular lean mass (ALM) showed casual association with increased risks of lung adenocarcinoma, melanoma, non-melanoma skin cancer, and lymphomas. Genetically predicted lower frailty whole-body lean mass (WBLM) were associated with a higher risk of lung squamous cell carcinoma (LUSC), gastric cancer, and lymphomas. Walking pace was casually correlated with decreased risks of LUSC and cervical cancer. These causal associations were largely independent of BF%, physical activity and smoking. Further analysis showed that GERD acted as a mediator affecting the causal associations between WBLM/walking pace and LUSC, with mediation proportions of 44.23% (95% CI: 0.07–81.36%) and 86.10% (95% CI: 36.41–135.8%) for the effects of WBLM and walking pace on LUSC, respectively. Systematic review and meta-analysis demonstrated that NSCLC patients with sarcopenia had a lower overall survival (HR = 2.49, 95% CI: 2.11–2.93), progression-free survival (HR = 1.89, 95% CI: 1.10–3.24), and recurrence-free survival rates (HR = 2.03, 95% CI: 1.40–2.95). Conclusion: Our findings suggest that interventions prioritizing muscle function, especially improving walking pace, may be more effective for reducing sarcopenia-related LUSC risk than solely increasing muscle mass, with gastroesophageal reflux disease (GERD) representing a potential – but still exploratory – intervention target along this pathway.
- 3 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (5) , 11365-11375
Open AccessCausal associations of sarcopenia-related traits with selected site-specific cancers and the mediating role of gastroesophageal reflux disease
Background: Both sarcopenia and cancers are common geriatric diseases leading to huge socioeconomic burdens. The causal impact of sarcopenia on selected site-specific cancers and the potential mediator was not clarified. Methods: Two-step, two-sample Mendelian randomization was performed to explore the causal impacts of sarcopenia on selected site-specific cancers with or without adjustment for body fat percentage (BF%), physical activity and smoking, and to evaluate proportions of the causal effects mediated by gastroesophageal reflux disease (GERD). Genetic instruments of sarcopenia-related traits, GERD, and selected site-specific cancers based on genome-wide association study were obtained from the UK Biobank, TRICL, and Japan Biobank. By searching relevant studies in PubMed, EMBASE, Cochrane Library, and Web of Science, we collected the data on the prognostic effects of sarcopenia on non-small cell lung cancer (NSCLC) for meta-analysis. Results: Lower appendicular lean mass (ALM) showed casual association with increased risks of lung adenocarcinoma, melanoma, non-melanoma skin cancer, and lymphomas. Genetically predicted lower frailty whole-body lean mass (WBLM) were associated with a higher risk of lung squamous cell carcinoma (LUSC), gastric cancer, and lymphomas. Walking pace was casually correlated with decreased risks of LUSC and cervical cancer. These causal associations were largely independent of BF%, physical activity and smoking. Further analysis showed that GERD acted as a mediator affecting the causal associations between WBLM/walking pace and LUSC, with mediation proportions of 44.23% (95% CI: 0.07–81.36%) and 86.10% (95% CI: 36.41–135.8%) for the effects of WBLM and walking pace on LUSC, respectively. Systematic review and meta-analysis demonstrated that NSCLC patients with sarcopenia had a lower overall survival (HR = 2.49, 95% CI: 2.11–2.93), progression-free survival (HR = 1.89, 95% CI: 1.10–3.24), and recurrence-free survival rates (HR = 2.03, 95% CI: 1.40–2.95). Conclusion: Our findings suggest that interventions prioritizing muscle function, especially improving walking pace, may be more effective for reducing sarcopenia-related LUSC risk than solely increasing muscle mass, with gastroesophageal reflux disease (GERD) representing a potential – but still exploratory – intervention target along this pathway.
- Open Access
- 13 June 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1880 (4) , 189370
Exploring synthetic lethality in cancer therapy: CRISPR-Cas9 technology offers new hope
- 13 June 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1880 (4) , 189370
Open AccessExploring synthetic lethality in cancer therapy: CRISPR-Cas9 technology offers new hope
- Open Access
- 15 April 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 14
Decoding Liver Cancer Prognosis: From Multi-omics Subtypes, Prognostic Models to Single Cell Validation
Purpose Hepatocellular carcinoma (HCC) is a highly aggressive tumor characterized by significant heterogeneity and invasiveness, leading to a lack of precise individualized treatment strategies and poor patient outcomes. This necessitates the urgent development of accurate patient stratification methods and targeted therapies based on distinct tumor characteristics. Experimental Design By integrating gene expression data from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus (GEO), we identified subtypes through a multi-omics consensus clustering approach amalgamated from 10 clustering techniques. Subsequently, we developed a prognostic model, employing machine learning algorithms, based on subtype classification features. Finally, by analyzing single cell sequencing data, we investigated the mechanisms driving prognostic variations among distinct subtypes. Results First, we developed a novel consensus clustering method that categorizes liver cancer patients into two subtypes, CS1 and CS2. Second, we constructed a prognostic prediction model, which demonstrated superior predictive accuracy compared to several models published in the past five years. Finally, we observed differences between CS1 and CS2 in various metabolic pathways, biological processes, and signaling pathways, such as fatty acid metabolism, hypoxia levels, PI3K-AKT and MIF signaling pathway.
- 15 April 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 14
Open AccessDecoding Liver Cancer Prognosis: From Multi-omics Subtypes, Prognostic Models to Single Cell Validation
Purpose Hepatocellular carcinoma (HCC) is a highly aggressive tumor characterized by significant heterogeneity and invasiveness, leading to a lack of precise individualized treatment strategies and poor patient outcomes. This necessitates the urgent development of accurate patient stratification methods and targeted therapies based on distinct tumor characteristics. Experimental Design By integrating gene expression data from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus (GEO), we identified subtypes through a multi-omics consensus clustering approach amalgamated from 10 clustering techniques. Subsequently, we developed a prognostic model, employing machine learning algorithms, based on subtype classification features. Finally, by analyzing single cell sequencing data, we investigated the mechanisms driving prognostic variations among distinct subtypes. Results First, we developed a novel consensus clustering method that categorizes liver cancer patients into two subtypes, CS1 and CS2. Second, we constructed a prognostic prediction model, which demonstrated superior predictive accuracy compared to several models published in the past five years. Finally, we observed differences between CS1 and CS2 in various metabolic pathways, biological processes, and signaling pathways, such as fatty acid metabolism, hypoxia levels, PI3K-AKT and MIF signaling pathway.
- Open Access
Decoding Liver Cancer Prognosis: From Multi-omics Subtypes, Prognostic Models to Single Cell Validation
Purpose: Hepatocellular carcinoma (HCC) is a highly aggressive tumor characterized by significant heterogeneity and invasiveness, leading to a lack of precise individualized treatment strategies and poor patient outcomes. This necessitates the urgent development of accurate patient stratification methods and targeted therapies based on distinct tumor characteristics. Experimental Design: By integrating gene expression data from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus (GEO), we identified subtypes through a multi-omics consensus clustering approach amalgamated from 10 clustering techniques. Subsequently, we developed a prognostic model, employing machine learning algorithms, based on subtype classification features. Finally, by analyzing single cell sequencing data, we investigated the mechanisms driving prognostic variations among distinct subtypes. Results: First, we developed a novel consensus clustering method that categorizes liver cancer patients into two subtypes, CS1 and CS2. Second, we constructed a prognostic prediction model, which demonstrated superior predictive accuracy compared to several models published in the past five years. Finally, we observed differences between CS1 and CS2 in various metabolic pathways, biological processes, and signaling pathways, such as fatty acid metabolism, hypoxia levels, PI3K-AKT and MIF signaling pathway.
Open AccessDecoding Liver Cancer Prognosis: From Multi-omics Subtypes, Prognostic Models to Single Cell Validation
Purpose: Hepatocellular carcinoma (HCC) is a highly aggressive tumor characterized by significant heterogeneity and invasiveness, leading to a lack of precise individualized treatment strategies and poor patient outcomes. This necessitates the urgent development of accurate patient stratification methods and targeted therapies based on distinct tumor characteristics. Experimental Design: By integrating gene expression data from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus (GEO), we identified subtypes through a multi-omics consensus clustering approach amalgamated from 10 clustering techniques. Subsequently, we developed a prognostic model, employing machine learning algorithms, based on subtype classification features. Finally, by analyzing single cell sequencing data, we investigated the mechanisms driving prognostic variations among distinct subtypes. Results: First, we developed a novel consensus clustering method that categorizes liver cancer patients into two subtypes, CS1 and CS2. Second, we constructed a prognostic prediction model, which demonstrated superior predictive accuracy compared to several models published in the past five years. Finally, we observed differences between CS1 and CS2 in various metabolic pathways, biological processes, and signaling pathways, such as fatty acid metabolism, hypoxia levels, PI3K-AKT and MIF signaling pathway.
- Open Access
- 2 April 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (4) , 1762-1772
Identification of risk factors of EGFR-TKIs primary resistance in lung adenocarcinoma patients and construction of a risk predictive model: a case-control study
Background: Lung cancer is one of the malignancies with the highest incidence and mortality rates. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are recommended as the first-line treatment for patients with EGFR-mutated lung adenocarcinoma (LUAD). However, some patients with EGFR-sensitive mutations develop primary resistance to EGFR-TKIs. This study aims to analyze the clinical characteristics of LUAD patients with primary resistance to EGFR-TKIs, identify independent risk factors for primary resistance, and establish a risk predictive model to provide reference for clinical decision-making. Methods: We collected data from LUAD patients with EGFR-sensitive mutations (19del/21L858R) who were hospitalized in our institution between 2020 and 2022 and received first-generation EGFR-TKIs with follow-up exceeding 6 months. These patients were categorized into primary resistance and sensitive groups based on treatment outcomes. We compared general clinical data, laboratory tests, and tumor-related characteristics between the two groups, analyzed risk factors for primary resistance to EGFR-TKIs, and constructed a risk predictive model. The model’s predictive value was comprehensively assessed using receiver operating characteristic (ROC) curves, calibration curves, and decision curves. Results: Serum neuron-specific enolase (NSE) concentration (P=0.03), serum pro-gastrin-releasing peptide (ProGRP) concentration (P=0.01), and Ki67 expression (PConclusions: Based on a single-center retrospective case-control study, we identified serum NSE concentration, ProGRP concentration, and Ki67 expression as independent risk factors for primary resistance to EGFR-TKIs in LUAD patients. We constructed and validated a risk predictive model based on these findings. This predictive model holds promise for clinical application, aiding in the development of personalized treatment strategies and providing a scientific basis for early identification of primary resistance patients.
- 2 April 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (4) , 1762-1772
Open AccessIdentification of risk factors of EGFR-TKIs primary resistance in lung adenocarcinoma patients and construction of a risk predictive model: a case-control study
Background: Lung cancer is one of the malignancies with the highest incidence and mortality rates. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are recommended as the first-line treatment for patients with EGFR-mutated lung adenocarcinoma (LUAD). However, some patients with EGFR-sensitive mutations develop primary resistance to EGFR-TKIs. This study aims to analyze the clinical characteristics of LUAD patients with primary resistance to EGFR-TKIs, identify independent risk factors for primary resistance, and establish a risk predictive model to provide reference for clinical decision-making. Methods: We collected data from LUAD patients with EGFR-sensitive mutations (19del/21L858R) who were hospitalized in our institution between 2020 and 2022 and received first-generation EGFR-TKIs with follow-up exceeding 6 months. These patients were categorized into primary resistance and sensitive groups based on treatment outcomes. We compared general clinical data, laboratory tests, and tumor-related characteristics between the two groups, analyzed risk factors for primary resistance to EGFR-TKIs, and constructed a risk predictive model. The model’s predictive value was comprehensively assessed using receiver operating characteristic (ROC) curves, calibration curves, and decision curves. Results: Serum neuron-specific enolase (NSE) concentration (P=0.03), serum pro-gastrin-releasing peptide (ProGRP) concentration (P=0.01), and Ki67 expression (PConclusions: Based on a single-center retrospective case-control study, we identified serum NSE concentration, ProGRP concentration, and Ki67 expression as independent risk factors for primary resistance to EGFR-TKIs in LUAD patients. We constructed and validated a risk predictive model based on these findings. This predictive model holds promise for clinical application, aiding in the development of personalized treatment strategies and providing a scientific basis for early identification of primary resistance patients.
- Open Access
- 1 March 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (3) , 1351-1366
Construction and validation of a prognostic model for stemness-related genes in lung adenocarcinoma
Original Article Construction and validation of a prognostic model for stemness-related genes in lung adenocarcinoma Hong Zhang, Chenlin Cao, Hua Xiong
- 1 March 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (3) , 1351-1366
Open AccessConstruction and validation of a prognostic model for stemness-related genes in lung adenocarcinoma
Original Article Construction and validation of a prognostic model for stemness-related genes in lung adenocarcinoma Hong Zhang, Chenlin Cao, Hua Xiong